	US 12,453,727 B2
	Montelukast salts and pharmaceutical compositions containing the same
Giuseppe Caliendo, Marigliano (IT); Giuseppe Cirino, Naples (IT); Ferdinando Fiorino, Benevento (IT); Francesco Frecentese, Aversa (IT); Marcelo Nicolas Muscara', Campinas (BR); Elisa Perissutti, Venafro (IT); Antonio Petti, Battipaglia (IT); Fiorentina Roviezzo, Bonea (IT); Vincenzo Santagada, Naples (IT); and Beatrice Severino, Mugnano di Napoli (IT)
Assigned to GENETIC S.P.A., Castel San Giorgio SA (IT)
Appl. No. 17/615,337
Filed by GENETIC S.P.A., Castel San Giorgio (IT)
PCT Filed Jun. 5, 2020, PCT No. PCT/EP2020/065629 § 371(c)(1), (2) Date Nov. 30, 2021, PCT Pub. No. WO2020/245358, PCT Pub. Date Dec. 10, 2020.
Claims priority of application No. 102019000008340 (IT), filed on Jun. 7, 2019.
Prior Publication US 2022/0218690 A1, Jul. 14, 2022
Int. Cl. A61K 31/47 (2006.01); A61K 31/137 (2006.01); A61K 31/167 (2006.01); A61P 11/06 (2006.01); A61P 11/08 (2006.01)

CPC A61K 31/47 (2013.01) [A61K 31/137 (2013.01); A61K 31/167 (2013.01); A61P 11/06 (2018.01); A61P 11/08 (2018.01)]

8 Claims

1. A salt formed between Montelukast and a ß2 adrenergic agonist, wherein the ß2 adrenergic agonist is, selected from the group consisting of Fenoterol, Orciprenaline, Salbutamol, Terbutaline, Bambuterol, Clenbuterol, Formoterol, Salmeterol, Vilanterol, Indacaterol and Olodaterol.